Market Tracker
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 11/21/2025 | CALL | $5.00 | 0 | 0 | |
| 11/21/2025 | CALL | $7.50 | 1 | 0 | |
| 11/21/2025 | CALL | $10.00 | 49 | 0 | |
| 11/21/2025 | CALL | $12.50 | 13 | 0 | |
| 11/21/2025 | CALL | $15.00 | 20 | 0 | |
| 11/21/2025 | CALL | $17.50 | 320 | 0 | |
| 01/16/2026 | PUT | $5.00 | 0 | 0 | |
| 01/16/2026 | PUT | $7.50 | 0 | 0 | |
| 01/16/2026 | PUT | $10.00 | 0 | 0 | |
| 01/16/2026 | PUT | $12.50 | 0 | 0 | |
| 01/16/2026 | PUT | $15.00 | 0 | 0 | |
| 11/21/2025 | PUT | $10.00 | 0 | -51 | -100.00% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
07/24 01:08 pm
Benzinga
Read moreCartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
05/08 07:00 am
GlobeNewswire Inc.
Read moreUS Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert
04/09 05:53 am
Benzinga
Read moreCAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
03/05 02:00 pm
GlobeNewswire Inc.
Read moreBy 2034, CAR-T Cell Therapy Market Set to Soar USD 8.7 Billion, at 1.80% CAGR: Prophecy Market Insights
08/27 08:49 am
GlobeNewswire Inc.
Read moreCartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research
07/03 02:30 pm
Zacks Investment Research
Read moreCartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
07/02 06:31 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces $130 Million Private Placement Equity Financing
07/02 06:31 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
07/02 06:30 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces New Employment Inducement Grant
06/06 07:05 am
GlobeNewswire Inc.
Read moreCartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
05/23 12:12 pm
Zacks Investment Research
Read moreCartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
05/22 07:00 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
05/13 04:30 pm
GlobeNewswire Inc.
Read moreWhat Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
05/13 12:00 pm
Zacks Investment Research
Read moreWall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
05/13 09:55 am
Zacks Investment Research
Read moreCartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
05/08 07:00 am
GlobeNewswire Inc.
Read moreWall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade
04/25 09:55 am
Zacks Investment Research
Read moreCartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
04/10 02:34 pm
Benzinga
Read moreDown -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
04/08 09:35 am
Zacks Investment Research
Read moreCartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
03/28 04:05 pm
GlobeNewswire Inc.
Read moreLivePerson And 2 Other Stocks Under $2 Insiders Are Buying
03/19 07:55 am
Benzinga
Read moreCartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
03/14 09:35 am
Zacks Investment Research
Read moreCartesian Therapeutics to Participate in Upcoming Investor Conferences
03/06 08:00 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces New Employment Inducement Grant
03/05 08:05 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
03/05 08:00 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces New Employment Inducement Grants
02/05 05:05 pm
GlobeNewswire Inc.
Read moreCartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
01/08 08:10 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
01/08 08:00 am
GlobeNewswire Inc.
Read moreEmergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
12/11 11:05 am
Zacks Investment Research
Read more